trū® Chitosan Files Patent on New USP Inhalant Product

BALATON, Minn., July 15, 2025 /PRNewswire/ -- trū® Chitosan, a brand of iterro Life Sciences, announced the introduction of trū Chitosan USP Inhalant—the first commercially available chitosan qualified for inhaled drug delivery, based on USP and USP 232 standards.

"Three years of research and five years of pilot scaled production has yielded another breakthrough product; a global first and only of its kind," stated Brian Knochenmus, iterro CEO. "trū Chitosan's USP Inhalant's level of purity advances decades of research into the medical potential of chitosan, bringing an unprecedented level of purity and consistency to inhaled applications. Our patent pending trū Chitosan USP Inhalant is a major achievement on our journey to producing the world's finest medical application chitosan."

Parimer Scientific, LLC (Easley, SC) is trū Chitosan's FDA-registered, CDMO partner. "As we scaled production, process improvement further reduced metal impurities resulting in trū Chitosan USP Inhalant," stated Dick Pace PhD and Founder of Parimer. "The iterro produced, pristine and homogeneous shrimp shell raw material and the collaborative work between iterro, the iterro Science & Medical Advisory Board, and the Parimer team resulted in a chitosan that not only meets the requirements of the United States Pharmacopeia (USP) monograph, but also the demanding USP 232 Limits of Impurities for Inhaled Delivery of Drug Substances."

trū Chitosan USP Inhalant joins the offerings of trū Chitosan to serve a variety of medical applications as an excipient, adjuvant, and active ingredient. "We started selling cGMP trū Chitosan in 2023 and we have attracted cancer therapies, surgical aides, hemostats, wound care, and nanoparticle applications to our unprecedented chitosan," stated Michael Ziebell COO, "trū Chitosan is a vertically integrated product of the USA. USP Inhalant trū Chitosan not only enables inhaled applications to address mycobacterial lung and similar diseases, but it demonstrates to the medical industry a new benchmark in chitosan purity—traceable, consistent, and specifically engineered for advanced medical applications, including inhaled delivery.

"In over 40 years of working with chitosan, I've never encountered a product with such clarity, purity, and molecular consistency. trū Chitosan USP Inhalant represents a milestone in medical-grade chitosan innovation", shared Samuel Hudson PhD, a globally renowned expert on the chitosan molecule and Professor Emeritus at North Carolina State University. I have never worked with a chitosan so perfectly clear in solution, and the USP Inhalant product is a testament to trū Chitosan's commitment to medical chitosan."

trū Chitosan is a brand of iterro Life Sciences and a product of the USA with capacity expansion plans in Madison, South Dakota. trū Chitosan is distributed by Hawkins Pharmaceuticals in the US. Please contact Chris Meyer (Hawkins National Sales Manager) on 612.617.8607. International inquiries, contact Michael Ziebell (trū Chitosan COO) on 507.337.6908.

Ready to integrate trū Chitosan into your research or product pipeline? Learn more at:

https://www.truchitosan.com/usp-inhalant

View original content to download multimedia:https://www.prnewswire.com/news-releases/tr-chitosan-files-patent-on-new-usp-inhalant-product-302505974.html

SOURCE Iterro, Inc.